PenderFund Capital Management’s Freeline Therapeutics Holdings plc American Depositary Shares FRLN Stock Holding History

PenderFund Capital Management’s Portfolio FRLN Stock Details FRLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-60,401	Closed	-$509K	–	143
2023 Q4	$509K	Buy	+60,401	New	+$323K	0.17%	59

PenderFund Capital Management's FRLN Position: Q1 2024 in Review

PenderFund Capital Management sold out of Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) in Q1 2024, closing a stake of 60,401 shares — an estimated $509K sold.

PenderFund Capital Management first reported a position in FRLN in Q4 2023 and held it in 1 quarter. The position peaked at $509K in Q4 2023. 0 funds tracked by Wall St. Rank hold FRLN as of Q1 2024.

PenderFund Capital Management reported no remaining Freeline Therapeutics Holdings plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
PenderFund Capital Management sold 60,401 Freeline Therapeutics Holdings plc American Depositary Shares shares in Q1 2024, an estimated $509K.
PenderFund Capital Management first reported a position in Freeline Therapeutics Holdings plc American Depositary Shares in Q4 2023 and held it in 1 quarter.
PenderFund Capital Management's Freeline Therapeutics Holdings plc American Depositary Shares position peaked at $509K in Q4 2023.
0 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings plc American Depositary Shares as of Q1 2024.

Based on PenderFund Capital Management's 13F filing for Q1 2024, filed 15 May 2024.